Korean J Thorac Cardiovasc Surg.  2011 Feb;44(1):39-43.

Surgery for Pulmonary Sclerosing Hemangioma: Lobectomy versus Limited Resection

• Park JS
• Kim K
• Shin S
• Shim H
• Kim HK

Abstract

BACKGROUND
Pulmonary sclerosing hemangioma is a rare thoracic tumor, and pathophysiology or clinical course of this tumor is not yet fully described. Furthermore, there is no consensus on the standard operative procedure for this tumor. MATERIAL AND METHODS: Medical records of thirty-two patients, who underwent surgical resection of pulmonary sclerosing hemangioma from 1996 to 2007, were retrospectively reviewed.
RESULTS
Nineteen patients underwent lobectomy and thirteen patients underwent limited resection. Video-assisted thoracoscopic surgery was performed in 9 patients in the latter group. Lymph node dissection was done in 21 patients, and one patient was found to have lymph node metastasis of the tumor. There was no postoperative complication, no early death and no tumor-related late mortality. The mean follow-up duration was 39.3 months (2 months~129 months), and all patients were free of local recurrence and distant metastasis during this period. There was no significant difference in patient's characteristics between the two groups, except that the mean hospital stay was shorter in limited resection group than in lobectomy group (p=0.0031).
CONCLUSION
Pulmonary sclerosing hemangioma usually requires surgical resection for both diagnosis and treatment. Limited resection can decrease hospital stay with a surgical outcome comparable to lobectomy, and may be preferred to lobectomy if sufficient resection margin can be achieved.

Keyword

Lung neoplasms; Surgery; Hemangioma

MeSH Terms

Consensus
Follow-Up Studies
Hemangioma
Humans
Length of Stay
Lung Neoplasms
Lymph Node Excision
Lymph Nodes
Medical Records
Neoplasm Metastasis
Postoperative Complications
Pulmonary Sclerosing Hemangioma
Recurrence
Retrospective Studies
Surgical Procedures, Operative
Thoracic Surgery, Video-Assisted